Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms RAP; Vienna-RAP-Study
- 30 Oct 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 30 Oct 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2019.
- 01 Jan 2015 Trial design presented at Trials.